期刊
MULTIPLE SCLEROSIS JOURNAL
卷 17, 期 5, 页码 630-633出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458510393770
关键词
clinical trials; methodology/study design; MRI; multiple sclerosis; surrogate endpoints
Recent studies have provided evidence for using magnetic resonance imaging (MRI) active lesions as surrogate for relapses and disability progression in multiple sclerosis (MS). However, the validity of MRI metrics as surrogate endpoints in MS is controversial. Furthermore, the extrapolation of previous results to novel therapies is not warranted. We tested here the validity of MRI surrogacy in MS studies on recently published trials of oral drugs. The 92% of observed effects of oral drugs on clinical outcomes resulted close to those predicted by MRI active lesions. This further validates MRI surrogacy in MS, with important implications for future trials planning.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据